- When evaluating the causality of an adverse event how to#
- When evaluating the causality of an adverse event pdf#
- When evaluating the causality of an adverse event trial#
Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Application filed by International Business Machines Corp filed Critical International Business Machines Corp Priority to US15/878,523 priority Critical patent/US11120913B2/en Assigned to INTERNATIONAL BUSINESS MACHINES CORPORATION reassignment INTERNATIONAL BUSINESS MACHINES CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Original Assignee International Business Machines Corp Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Fokoue-Nkoutche Katherine Shen Ping Zhang Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active, expires Application number US15/878,523 Other versions US20190228864A1
When evaluating the causality of an adverse event pdf#
Google Patents Evaluating drug-adverse event causality based on an integration of heterogeneous drug safety causality modelsĭownload PDF Info Publication number US11120913B2 US11120913B2 US15/878,523 US201815878523A US11120913B2 US 11120913 B2 US11120913 B2 US 11120913B2 US 201815878523 A US201815878523 A US 201815878523A US 11120913 B2 US11120913 B2 US 11120913B2 Authority US United States Prior art keywords drug causality computer executed risk patient Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US11120913B2 - Evaluating drug-adverse event causality based on an integration of heterogeneous drug safety causality models
![when evaluating the causality of an adverse event when evaluating the causality of an adverse event](https://us-static.z-dn.net/files/de2/98bede5e144592a8a4d28dbf6cc0cca0.png)
He has additional training in nephrology and a master’s degree in clinical research.US11120913B2 - Evaluating drug-adverse event causality based on an integration of heterogeneous drug safety causality models Jamison Chang, MD, medical officer at Rho, is a board-certified internist with more than 15 years of clinical experience. Gerald Klein, MD, principal, MedSurgPI, is a former professor of clinical medicine and pediatrics at the University of California, Irvine. Get there with Assessing Adverse Event Causality: A Guide for Investigators and Sites.
When evaluating the causality of an adverse event trial#
Patient safety and trial success will be yours when you make critical decisions about adverse events with ease. Whether the terms “probable” and “possible” should be used.
When evaluating the causality of an adverse event how to#
How to apply the dechallenge/rechallenge test.
![when evaluating the causality of an adverse event when evaluating the causality of an adverse event](https://ars.els-cdn.com/content/image/1-s2.0-S0933365717306152-fx1.jpg)
![when evaluating the causality of an adverse event when evaluating the causality of an adverse event](https://www.centerwatch.com/ext/resources/products/Assessing-Adverse-Event-Causality-500.jpg)
You’re in the middle of an “uh oh” moment: a patient in your clinical trial has an adverse health event.